EIF2AK3 and familial pancreatic carcinoma: Similarly, Anlotinib (AL3818), a drug that has been proved to have anti-tumor activity recently, has an anti-proliferation effect on pancreatic cancer cells related to PERK by increase the accumulation of reactive oxygen species in cancer cells activating of the PERK/eIF2α/ATF4 pathway 25.